SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Similar documents
Supplement materials:

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture

A n aly tical m e t h o d s

Chapter Two Renal function measures in the adolescent NHANES population

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Treatment disparities for patients diagnosed with metastatic bladder cancer in California

Chapter 4: Cardiovascular Disease in Patients With CKD

Supplementary Appendix

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

Supplementary Appendix

Supplementary Online Content

egfr > 50 (n = 13,916)

Supplementary Appendix

USRDS UNITED STATES RENAL DATA SYSTEM

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Association between multiple comorbidities and self-rated health status in middle-aged and elderly Chinese: the China Kadoorie Biobank study

Supplementary Online Content

Depressive Symptoms and Chronic Kidney Disease: Results from the National Health and Nutrition Examination Survey (NHANES)

Chapter 1: CKD in the General Population

Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries

Chronic kidney disease (CKD) has received

The University of Mississippi School of Pharmacy

Predicting and changing the future for people with CKD

Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly?

Supplementary Online Content

Variable Included. Excluded. Included. Excluded

SUPPLEMENTAL MATERIAL

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

David Ramenofsky, MD Bryan Kestenbaum, MD

Effect of Saxagliptin on Renal Outcomes in the SAVOR TIMI- 53 study- Appendixes:

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Online Content

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Zhao Y Y et al. Ann Intern Med 2012;156:

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world

Supplementary material

Supplementary Online Content

Supplementary Online Content

Ashberyh CHAPTER. John

Chapter 2: Identification and Care of Patients With CKD

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Substance Use Among Potential Kidney Transplant Candidates and its Impact on Access to Kidney Transplantation: A Canadian Cohort Study

Gender Differences in Physical Inactivity and Cardiac Events in Men and Women with Type 2 Diabetes

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.

Magnetic resonance imaging, image analysis:visual scoring of white matter

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

CVD risk assessment using risk scores in primary and secondary prevention

Supplementary Online Content

Status of the CKD and ESRD treatment: Growth, Care, Disparities

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

ARIC Manuscript Proposal # 1518

Chapter 2: Identification and Care of Patients With CKD

Definitions of chronic conditions used to define the number of serious comorbidities in the study.

The incidence and prevalence of hypertension

Chapter 2: Identification and Care of Patients with CKD

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

Supplementary Online Content

Blood Pressure Measurement in SPRINT

T. Suithichaiyakul Cardiomed Chula

KEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56

Social Participation Among Veterans With SCI/D: The Impact of Post Traumatic Stress Disorder

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Supplementary Appendix

Association of plasma uric acid with ischemic heart disease and blood pressure:

Blood Pressure Monitoring in Chronic Kidney Disease

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Effective Health Care Program

Supplementary Online Content

Know Your Number Aggregate Report Single Analysis Compared to National Averages

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Smoking Status and Body Mass Index in the United States:

Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Mental health and substance use among US adults: An analysis of 2011 Behavioral Risk Factor Surveillance Survey

Cardiovascular Risk Reduction in Kidney Transplant Recipients

KEEP 2009 Summary Figures

APPENDIX: Supplementary Materials for Advance Directives And Nursing. Home Stays Associated With Less Aggressive End-Of-Life Care For

Supplementary Online Content

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Supplementary Appendix

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

AGING KIDNEY IN HIV DISEASE

High Risk OSA n = 5,359

HTA ET DIALYSE DR ALAIN GUERIN

Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64

Self Perceived Oral Health Status, Untreated Decay, and Utilization of Dental Services Among Dentate Adults in the United States: NHANES

Supplementary Appendix

Appendix Identification of Study Cohorts

Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies

Predicting Short Term Morbidity following Revision Hip and Knee Arthroplasty

Statistical Fact Sheet Populations

Adam T. Whaley-Connell, MD, James R. Sowers, MD, Joseph A. Vassalotti, MD, Moro O. Salifu, MD, MPH, Suying Li, PhD,

Hypertension. Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008

Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments

Transcription:

Supplementary Figure S1. Cohort definition flow chart.

Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not Total population (933,211) Incident CKD (n=180,343) No incident CKD (n=750,325) Age (years) 64±11 65±10 63±11 Gender (male) n (%) 901,958 (97) 175,877 (98) 723,652(96) Baseline egfr (ml/min./1.73m 2 ) 82±15 78±13 83±15 BMI (kg/m 2 ) 31±5 31±5 31±5 Serum albumin (g/l) 40.2±4.5 39.4±4.7 40.4±4.4 Income (USD) 23,389 (12,354-34,263) 22,708 (12,635-32,885) 23,586 (12,295-34,820) Race n (%): White 663,394 (77) 132,423 (77) 530,971 (77) African-American 152,954 (18) 30,870 (18) 122,084 (18) Hispanic 25,441 (3) 4,871 (3) 20,570 (3) Other Race 19,770 (2) 3,511 (2) 16,259 (2) Marital status: Married 540,202 (60) 100,468 (57) 439,734(61) Single 67,645 (8) 11,834 (7) 55,811 (8) Divorced 210,805 (23) 42,396 (24) 168,409 (23)

Widow 79,480 (9) 19,706 (11) 59,774 (8) Service connection 400,064 (43) 77,423 (43) 322,641 (43) Comorbidities n (%): Cardiovascular Disease 167,292 (18) 44,964 (25) 122,328 (16) CHF 77,493 (8) 27,592 (15) 49,901 (7) Hypertension 748,136 (80) 161,656 (90) 586,480 (78) Cerebrovascular Disease 82,809 (9) 22,509 (12) 60,300 (8) Peripheral Arterial Disease 87,418 (9) 26,777 (15) 60,641 (8) Chronic Lung Disease 184,268 (19) 41,497 (23) 142,771 (19) Dementia 10,191 (1) 2,168 (1) 8,023(1) Rheumatologic Disease 13,065 (1) 3,125 (2) 8,023 (1) Peptic Ulcer 18,593 (2) 4,567 (3) 14,026 (2) Mild/Severe liver disease 15,235 (2) 3,738 (2) 11,497 (2) Hemiplegia 4,995 (0.5) 1,115 (0.6) 3,880 (0.5) All malignancies 107,451 (12) 24,470 (14) 82,981 (11) AIDS/HIV 3,462 (0.4) 920 (0.5) 2,542 (0.3) Post-Traumatic Stress Disorder (PTSD) 96,804 (10) 19,633 (11) 77,171 (10) Statin use 191,070 (21) 41,285 (23) 149, 785 (20) Anti-hypertensive medication use 516,384 (55) 113,724 (63) 402,660 (54) Abbreviations: egfr = estimated glomerular filtration rate; BMI = Body Mass Index; USD = US dollars; CHF = congestive heart failure;

Supplementary Table S2. Predictors of Depression using logistic regression analysis Odds Ratio (95% confidence interval of Odds ratio) Age (+10 year) 0.95 (0.95-0.96) Gender: female vs male (ref.) 1.62 (1.57-1.66) Race: White (ref.) 1 N/A African-American 0.7 (0.69-0.71) Hispanic 1.01 (0.98-1.03) Other Race 0.77 (0.75-0.8) Income (+1 log) 0.92 (0.91-0.92) Unmarried Yes vs NO 1.09 (1.08-1.1) Baseline egfr (+10 ml/min./1.73m 2 ) 1 (1-1) Presence of Cardiovascular Disease vs absence of Cardiovascular Disease (ref.) 1.2 (1.18-1.21) Presence of Congestive Heart Failure vs absence of Congestive Heart Failure (ref.) 1.28 (1.25-1.3) Presence of CVD vs absence of CVD (ref.) 1.45 (1.42-1.47) Presence of Peripheral Arterial Disease vs absence of Peripheral Arterial Disease (ref.) 1.29 (1.27-1.31) Presence of Chronic Lung Disease vs absence of Chronic Lung Disease (ref.) 1.69 (1.67-1.71) Presence of dementia vs absence of dementia (ref.) 4.11 (3.92-4.31) Presence of Rheumatologic Disease vs absence of Rheumatologic Disease (ref.) 1.36 (1.31-1.42) Presence of malignancy vs absence of malignancy (ref.) 1.21 (1.19-1.23)

Presence of AIDS/HIV vs absence of AIDS/HIV (ref.) 1.39 (1.29-1.5) Presence of Hypertension vs absence of Hypertension (ref.) 1.18 (1.17-1.2) Body mass index (+1 kg/m 2 ) 0.99 (0.99-1) Albumin (+1 g/dl) 0.75 (0.74-0.76) Abbreviations: egfr = estimated glomerular filtration rate; CVD = cardiovascular disease;

Supplementary Table S3. Sensitivity analyses assessing the association between baseline depression and mortality, incident stroke and CHD separately in patients who maintained egfr 60 ml min 1 1.73 m 2 versus in patients who developed incident CKD during the follow-up period. Outcome Patients who maintained egfr 60 ml min 1 1.73 m 2 during the follow-up period Hazard Ratio (95% CI) Patients who developed incident CKD during the follow-up period Hazard Ratio (95% CI) Mortality 1.32 (1.31, 1.34) 1.15 (1.12, 1.17) Incident coronary heart disease 1.21 (1.18, 1.25) 1.05 (1.01, 1.09) Incident stroke 1.34 (1.29, 1.39) 1.20 (1.14, 1.26) The models were adjusted for the following covariates: age, gender, race/ethnicity, marital status, baseline egfr, comorbidities at baseline (hypertension, cardiovascular disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, lung disease, dementia, rheumatic disease, malignancy, HIV/AIDS and Post-Traumatic Stress Disorder) and the use of statins or anti-hypertensive medications, body mass index and serum albumin level. Abbreviations: coronary heart disease = coronary heart disease; egfr = estimated glomerular filtration rate; CKD = chronic kidney disease; CI = confidence interval

Supplementary Figure S2. Multivariable adjusted associations between incident CKD and the presence of depression at baseline compared to those without depression in pre-defined subgroups of the study cohort. The models were adjusted for the following covariates: age, gender, race/ethnicity, marital status, baseline egfr, comorbidities at baseline (hypertension, cardiovascular disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, lung disease, dementia, rheumatic disease, malignancy, HIV/AIDS and Post-Traumatic Stress Disorder) and the use of statins or anti-hypertensive medications, body mass index and serum albumin level. Abbreviations: AA = African American; yr = year; BMI = Body Mass Index; egfr /= estimated Glomerular Filtration Rate; No cerebrovascular = no cerebrovascular disease at baseline; Cerebrovascular = cerebrovascular disease is present at baseline; Non CVD = no cardiovascular disease at baseline; CVD = Cardiovascular Disease is present at baseline.

Supplementary Figure S3. Multivariable adjusted associations between all-cause mortality and the presence of depression at baseline compared to those without depression in pre-defined subgroups of the study cohort. The models were adjusted for the following covariates: age, gender, race/ethnicity, marital status, baseline egfr, comorbidities at baseline (hypertension, cardiovascular disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, lung disease, dementia, rheumatic disease, malignancy, and HIV/AIDS and Post-Traumatic Stress Disorder) and the use of statins or antihypertensive medications, body mass index and serum albumin level. Abbreviations: AA = African American; yr = year; BMI = Body Mass Index; egfr /= estimated Glomerular Filtration Rate; No cerebrovascular = no cerebrovascular disease at baseline; Cerebrovascular = cerebrovascular disease is present at baseline; Non CVD = no cardiovascular disease at baseline; CVD = Cardiovascular Disease is present at baseline.